Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients

International Journal of Urology

Volumn 15, Issue 1, 2008, Pages 106-109

  Takenaka, Atsushi ^a   Yamada, Yuji ^a   Kurahashi, Toshifumi ^a   Soga, Hideo ^a   Miyake, Hideaki ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Estramustine; Hormone refractory; Prostate cancer; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; JAPANESE; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; PERIPHERAL EDEMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; THROMBOCYTOPENIA; THROMBOSIS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 37849017949     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01929.x     Document Type: Article

References (9)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J. Clin. 1997 47 : 5 27.
2. Kato H. Cancer statistics in Japan. Foundation for Promotion Cancer Research, Tokyo. 2007
3. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin. Oncol. 2001 28 : 8 15.
4. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br. J. Urol. 1997 79 : 196 202.
5. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 1999 17 : 958 67.
6. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol. 2001 19 : 2509 16.
7. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002 94 : 1457 65.
8. Wada Y, Kikuchi K, Takahashi W et al. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Cancer Chemother. Pharmacol. 2008; 61: 53-61.
9. Semb KA, Aamdal S, Oin P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J. Clin. Oncol. 1998 16 : 3426 32.